Product
Newnorm
1 clinical trial
1 indication
Indication
Primary Immune DeficiencyClinical trial
Prospective, Open-label, Single-arm, Multicentre Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency DiseasesStatus: Recruiting, Estimated PCD: 2025-06-01